May 24, 2023
Sponsored By:
Speakers
Session Description
<div class="ag87-crtemvc-hsbk"><div class="css-vsf5of"><p class="carina-rte-public-DraftStyleDefault-block"><span style="color: rgb(0,0,0);">The COVID-19 pandemic has highlighted the need for more efficient and versatile vaccine development. Synthetic biology offers a unique solution to this challenge by leveraging mRNA-based vaccines. The vision of the Digital to Biological Converter (DBC) is to enable the printing of vaccines from digital information across the globe, and this technology is now more relevant than ever. Today, mRNA has the spotlight and we have only scratched the surface of its potential as a platform for sophisticated therapeutics and targeting. Telesis Bio addresses the bottlenecks in mRNA-based discovery by offering one step and two-step mRNA solutions for vaccine discovery. We will showcase our collaboration with RNAimmune, demonstrating the adoption of the BioXp platform, enabling broader and faster vaccine screening. Additionally, we will provide an update on SOLA and its utility for vaccine technology. Finally, we will discuss the future of mRNA-based vaccines and the potential of RNA encapsulation on the BioXp platform.</span></p></div></div>